paclitaxel

Type: Keyphrase
Name: paclitaxel
First reported 6 hours ago - Updated 6 hours ago - 1 reports

New Taxoids Study Results Reported from Polish Academy of Sciences

By a News Reporter-Staff News Editor at Biotech Week -- Investigators discuss new findings in Taxoids. According to news reporting originating in Krakow, Poland , by NewsRx journalists, research stated, "Nanoencapsulation is a promising solution for the ... [Published HispanicBusiness.com - 6 hours ago]
First reported 7 hours ago - Updated 7 hours ago - 1 reports

Reports Outline Chemotherapy Study Findings from University of Tokyo

By a News Reporter-Staff News Editor at Biotech Week -- Fresh data on Drugs and Therapies are presented in a new report. According to news reporting originating in Tokyo, Japan , by NewsRx journalists, research stated, "Peritoneal metastasis of gastric ... [Published 4 Traders - 7 hours ago]
First reported Apr 15 2014 - Updated 12 hours ago - 2 reports

Pivotal Phase III Study Evaluates Veliparib (ABT-888) in Lung Cancer Patients

Treatment added to standard chemotherapy with carboplatin and paclitaxelAbbVie has announced the initiation of a global phase III clinical trial evaluating the safety and efficacy of its investigational compound veliparib (ABT-888) in patients with previously ... [Published P&T Community - 12 hours ago]
First reported Apr 15 2014 - Updated 20 hours ago - 6 reports

AbbVie announces phase III trial of lung cancer drug

:04 in Pharmaceutical Company Product News AbbVie has announced the commencement of a new phase III clinical trial of a promising therapy for advanced lung cancer. The global study will evaluate the safety and efficacy of the investigational compound ... [Published Zenopa - 20 hours ago]
First reported Apr 15 2014 - Updated Apr 15 2014 - 2 reports

Puma Biotechnology: ISPY2 Data Added Little To The Neratinib Conversation

By Poonam A. Arora:At the American Association for Cancer Research (AACR) 2014 meeting, Puma Biotechnology ( PBYI ) presented additional data on their Phase II ISPY2 study that evaluated Neratinib + Paclitaxel against Herceptin + Paclitaxel as treatment ... [Published BioPortfolio - Apr 15 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

Oncology: Reports Summarize Breast Cancer Study Results from Texas Technical University

Today's Medical & Research News2014 APR 15 -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Data detailed on Oncology have been presented. According to news reporting originating in Lubbock, Texas, by NewsRx journalists, research stated, ... [Published NewsRX - Apr 15 2014]
First reported Apr 11 2014 - Updated Apr 11 2014 - 1 reports

Here's What's Behind Puma's Crash

Alan Auerbach, the former CEO of Cougar Biotechnology -- the company that developed Johnson & Johnson 's widely successful Zytiga prostate cancer drug -- hopes he has another blockbuster potential drug on his hands at Puma Biotechnology ( NYSE: PBYI   ... [Published Motley Fool Discussion Boards - Apr 11 2014]
First reported Apr 11 2014 - Updated Apr 11 2014 - 1 reports

Reports Summarize Breast Cancer Study Results from Texas Technical University

(NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Data detailed on Oncology have been presented. According to news reporting originating in Lubbock, Texas, by NewsRx journalists, research stated, "Previously, we reported that ... [Published NewsRX - Apr 11 2014]
First reported Apr 10 2014 - Updated Apr 10 2014 - 2 reports

Company News: New Clinical Data Demonstrate Strong Synergy between Cancer Vaccine ISA101 and Chemotherapy

-      Data presented at the AACR Annual Meeting 2014-      Potential new treatment being developed for patients with late-stage cervical cancerISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed therapeutic ... [Published Akampion - Apr 10 2014]
First reported Apr 10 2014 - Updated Apr 10 2014 - 2 reports

Puma presents positive results from phase II trial of its investigational drug PB272

Puma Biotechnology, a development stage biopharmaceutical company, announced the presentation of positive results from the phase II clinical trial of Puma's investigational drug PB272 (neratinib) for the neoadjuvant treatment of breast cancer (I-SPY 2 ... [Published PharmaBiz - Apr 10 2014]
First reported Apr 10 2014 - Updated Apr 10 2014 - 1 reports

Oncolytics Reports Additional Data on Reolysin - Analyst Blog

Oncolytics Biotech Inc. (NASDAQ: ONCY[1]) reported additional encouraging data from the REO 018 (n = 167) study on its oncology candidate, Reolysin. The randomized, double blinded, two-arm, multi-center study compared the use of Reolysin plus Bristol-Myers ... [Published DailyMe.Com - Apr 10 2014]
First reported Mar 19 2014 - Updated Mar 19 2014 - 3 reports

Kinex and Zenith Technology to Initiate Clinical Studies of an Oral Form of Paclitaxel (Oraxol) in New Zealand

SOURCE Kinex PharmaceuticalsBUFFALO, N.Y.Dr. Rudolf Kwan"Paclitaxel is a commonly used intravenous chemotherapy drug that has to be administered by IV drip, meaning patients are tied to weekly visits to hospitals to receive treatment. Patients need to ... [Published KSLA - Mar 19 2014]

Quotes

The following quote was obtained by the news editors from the background information supplied by the inventors: "Polyurethanes represent a main class of synthetic elastomers employed for long-term, medical implants as they present tunable chemical properties, excellent mechanical properties, good blood compatibility, and also can be designed to degrade in biological environments [A. Rechichi et al., J Biomed . Mater. Res., 84-A, 847 (2008)]. More specifically, polyether-urethane (PEU) and polyether-urethane-urea (PEUU) elastomers have long been considered ideal for use in many implanted devices, in spite of occasionally cited drawbacks [ M A Schubert et al., J Biomed . Mater. Res., 35, 319 (1997); B Ward et al., J Biomed . Mater. Res., 77-A, 380 (2008)]. Of the cited drawbacks are those associated with (1) the generation of aromatic diamines, which are considered to be toxic upon degradation of segmented copolymers made using aromatic diisocyanates for interlinking; (2) chain degradation due to oxidation or radiation degradation of the polyether component of segmented copolymers, and particularly those which encounter frequent mechanical stresses in the biological environment; and (3) chemical degradation in chemically and mechanically hostile biological environments of the urethane links of segmented copolymers and particularly those comprising reactive aromatic urethane linkages."
...According to news reporting originating in Krakow, Poland , by NewsRx journalists, research stated, "Nanoencapsulation is a promising solution for the delivery of chemotherapeutics to tumors. A method of preparation of drug-loaded nanocapsules based on the liquid core encapsulation by a sequential adsorption of a polyelectrolyte is described."
...According to news reporting originating in Tokyo, Japan , by NewsRx journalists, research stated, "Peritoneal metastasis of gastric cancer has extremely poor clinical outcomes. Recently, we developed a combination chemotherapy that used intraperitoneal (IP) paclitaxel (PTX) and produced excellent antitumor effects against peritoneal lesions."
"Still other objects and advantages of the present disclosure will become readily apparent by those skilled in the art from the following detailed description, wherein it is shown and described only the preferred embodiments, simply by way of illustration of the best mode. As will be realized, the disclosure is capable of other and different embodiments, and its several details are capable of modifications in various obvious respects, without departing from the disclosure. Accordingly, the description is to be regarded as illustrative in nature and not as restrictive"

More Content

All (288) | News (269) | Reports (0) | Blogs (9) | Audio/Video (0) | Fact Sheets (4) | Press Releases (5)
sort by: Date | Relevance
Patent Issued for Absorbable Crystalline Polyet... [Published HispanicBusiness.com - 6 hours ago]
New Taxoids Study Results Reported from Polish ... [Published HispanicBusiness.com - 6 hours ago]
Reports Outline Chemotherapy Study Findings fro... [Published 4 Traders - 7 hours ago]
Patent Application Titled "Derivatives of Sulin... [Published HispanicBusiness.com - 11 hours ago]
IN.PACT Admiral Drug-coated Balloon Outperforms... [Published Diagnostic & Invasive Cardiology - 11 hours ago]
Pivotal Phase III Study Evaluates Veliparib (AB... [Published P&T Community - 12 hours ago]
Oxford Finance and Silicon Valley Bank Expand E... [Published TickerTech.com - 17 hours ago]
AbbVie announces phase III trial of lung cancer... [Published Zenopa - 20 hours ago]
AbbVie starts second Phase III veliparib study [Published BioPortfolio - Apr 16 2014]
Electroporation-Based Therapies for Cancer. Woo... [Published Research and Markets - Apr 16 2014]
Secreted Clusterin Gene Silencing Enhances Chem... [Published Sexual Development - Apr 16 2014]
AbbVie’s Lung Cancer Drug Advances to Phase 3 [Published Drug Discovery and Development - Apr 15 2014]
Phase III trial of PARP inhibitor for lung canc... [Published Oncology Report - Apr 15 2014]
Abbvie announces initiation of pivotal Phase II... [Published European Pharmaceutical Review - Apr 15 2014]
Puma Biotechnology: ISPY2 Data Added Little To ... [Published BioPortfolio - Apr 15 2014]
AbbVie Announces Initiation of Pivotal Phase II... [Published DailyMe.Com - Apr 15 2014]
AbbVie Begins Phase III Trial Of Veliparib For ... [Published RTTNews.com - Apr 15 2014]
AbbVie Announces Initiation of Pivotal Phase II... [Published Barchart - Apr 15 2014]
AbbVie Announces Initiation of Pivotal Phase II... [Published Benzinga.com - Apr 15 2014]
Clinical Trial to Test Modified Citrus Pectin i... [Published WSET - Apr 15 2014]
Puma Biotechnology: ISPY2 Data Added Little To ... [Published Seeking Alpha - Apr 15 2014]
Oncology: Reports Summarize Breast Cancer Study... [Published NewsRX - Apr 15 2014]
"What on earth is this thing and how exactly ca... [Published American Chemical Society - Apr 15 2014]
Variants of humanized immunomodulatory monoclon... [Published PharmCast - Apr 15 2014]
Revamp the FDA Drug-Approval Process [Published Diabetes Care - Apr 14 2014]
Clinical validation of the EndoPredict test in ... [Published 7thSpace - Apr 12 2014]
Here's What's Behind Puma's Crash [Published Motley Fool Discussion Boards - Apr 11 2014]
Bevacizumab in Treatment of High-Risk Ovarian C... [Published The Oncologist - Apr 11 2014]
Sorrento Therapeutics doses first patient in ca... [Published Individual.com - Apr 11 2014]
Strong and Sustained Response to Treatment with... [Published Sexual Development - Apr 11 2014]
1 2 3 4 5 6 7 8 9 10
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Oncolytics Biotech® Inc. Announces Additional D... [Published PR Newswire: Health - Apr 08 2014]
CALGARY, April 8, 2014 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC) (NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced additional data from the Company's randomized, double-blinded clinical study examining REOLYSIN® in combination with ...
Kinex and Zenith Technology to Initiate Clinica... [Published PR Newswire: Health - Mar 19 2014]
BUFFALO, N.Y., March 19, 2014 /PRNewswire/ -- Kinex Pharmaceuticals announced today to having received regulatory and ethics approvals to initiate the first clinical study of an oral form of paclitaxel (Oraxol) in Dunedin Hospital in Otago, New Zealand.  ...
Eisai Announces Initiation of a Phase 3 Trial o... [Published PR Newswire: Health - Feb 27 2014]
WOODCLIFF LAKE, N.J., Feb. 27, 2014 /PRNewswire/ -- Eisai Inc. today announced the start of a large, randomized Phase 3 trial to compare the efficacy, safety and tolerability of eribulin mesylate to standard weekly paclitaxel as a first- or second- ...
[tt] [GRG] ABS: High dose vitamin C in cancer -... [Published TranshumanTech - Feb 14 2014]
http://stm.sciencemag.org/content/6/222/222ra18 Sci Transl Med 5 February 2014: Vol. 6, Issue 222, p. 222ra18 Sci. Transl. Med. DOI: 10.1126/scitranslmed.3007154•Research Article CANCER High-Dose Parenteral Ascorbate Enhanced Chemosensitivity of ...
Vitamin C for cancer: Trying to rise from the g... [Published ScienceBlogs : Combined Feed - Feb 10 2014]
There are certain things that can happen that are the equivalent of the Bat Signal to me; that is, if you can swallow the idea of me being in any way like Bruce Wayne. Call them the Cancer Signal, if you will. When I see the Cancer Signal, I know that ...
1 2

Press Releases

sort by: Date | Relevance
Oasmia Receives FDA Conditional Approval For It... [Published GlobeNewswire: Acquisitions News - Feb 28 2014]
OncoMed Pharmaceuticals Commences Third Phase 1... [Published GlobeNewswire: Advertising News - Feb 20 2014]
Cell Therapeutics Reaches Agreement to Reacquir... [Published Financial Services - Jan 13 2014]
Oasmia Announces Successful FDA Pre-Approval In... [Published GlobeNewswire: Acquisitions News - Dec 03 2013]
OncoMed Pharmaceuticals Initiates First Phase 1... [Published GlobeNewswire: Advertising News - Oct 29 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.